Vistagen Therapeutics Inc (VTGN)
2.58
+0.05
(+1.98%)
USD |
NASDAQ |
Nov 22, 16:00
2.565
-0.02
(-0.58%)
After-Hours: 20:00
Vistagen Therapeutics Enterprise Value: -25.74M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | -25.74M |
| November 21, 2024 | -27.13M |
| November 20, 2024 | -24.91M |
| November 19, 2024 | -23.24M |
| November 18, 2024 | -23.79M |
| November 15, 2024 | -24.35M |
| November 14, 2024 | -21.57M |
| November 13, 2024 | -19.06M |
| November 12, 2024 | -16.00M |
| November 11, 2024 | -13.49M |
| November 08, 2024 | -10.15M |
| November 07, 2024 | -10.71M |
| November 06, 2024 | -11.26M |
| November 05, 2024 | -12.35M |
| November 04, 2024 | -10.46M |
| November 01, 2024 | -13.44M |
| October 31, 2024 | -14.25M |
| October 30, 2024 | -13.98M |
| October 29, 2024 | -15.06M |
| October 28, 2024 | -15.60M |
| October 25, 2024 | -16.14M |
| October 24, 2024 | -15.60M |
| October 23, 2024 | -15.60M |
| October 22, 2024 | -13.71M |
| October 21, 2024 | -16.41M |
| Date | Value |
|---|---|
| October 18, 2024 | -14.52M |
| October 17, 2024 | -14.79M |
| October 16, 2024 | -15.87M |
| October 15, 2024 | -18.58M |
| October 14, 2024 | -15.87M |
| October 11, 2024 | -15.60M |
| October 10, 2024 | -15.87M |
| October 09, 2024 | -18.58M |
| October 08, 2024 | -18.04M |
| October 07, 2024 | -19.93M |
| October 04, 2024 | -16.14M |
| October 03, 2024 | -17.77M |
| October 02, 2024 | -16.41M |
| October 01, 2024 | -14.79M |
| September 30, 2024 | -16.14M |
| September 27, 2024 | -25.30M |
| September 26, 2024 | -27.20M |
| September 25, 2024 | -25.58M |
| September 24, 2024 | -26.93M |
| September 23, 2024 | -26.39M |
| September 20, 2024 | -23.14M |
| September 19, 2024 | -27.20M |
| September 18, 2024 | -27.33M |
| September 17, 2024 | -24.49M |
| September 16, 2024 | -23.14M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-32.14M
Minimum
Jun 20 2024
562.89M
Maximum
Jul 01 2021
100.70M
Average
31.66M
Median
Jul 17 2020
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.608M |
| Palatin Technologies Inc | 16.38M |
| iBio Inc | 14.05M |
| Theriva Biologics Inc | -12.68M |
| Oragenics Inc | 2.314M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.96M |
| Revenue (Quarterly) | 0.183M |
| Total Expenses (Quarterly) | 14.41M |
| EPS Diluted (Quarterly) | -0.42 |
| Profit Margin (Quarterly) | -7.08K% |
| Earnings Yield | -52.03% |
| Normalized Earnings Yield | -52.03 |